Search details
1.
Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases.
J Rheumatol
; 51(3): 305-312, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-37839812
2.
Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.
J Rheumatol
; 51(5): 529-537, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38428964
3.
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.
Rheumatology (Oxford)
; 2023 Dec 09.
Article
in English
| MEDLINE | ID: mdl-38070152
4.
Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
Ann Rheum Dis
; 83(5): 680-682, 2024 Apr 11.
Article
in English
| MEDLINE | ID: mdl-38199795
5.
Risk factors and outcomes for repeat COVID-19 infection among patients with systemic autoimmune rheumatic diseases: A case-control study.
Semin Arthritis Rheum
; 63: 152286, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37913612
6.
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study.
Lancet Rheumatol
; 5(3): e139-e150, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36844970
7.
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study.
medRxiv
; 2023 Oct 09.
Article
in English
| MEDLINE | ID: mdl-37873462
8.
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
medRxiv
; 2022 Oct 30.
Article
in English
| MEDLINE | ID: mdl-36324801
Results
1 -
8
de 8
1
Next >
>>